



Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases

Matthew L. Thomas¹, Gavin Shaddick², Rachel Charlton³, Charlotte Cavill⁴, Richard Holland⁴, Florenzo Iannone⁵ , Giovanni Lapadula⁵, Simona Lopriore⁵, Jakub Závada⁶, Michal Uher⁷, Karel Pavelka⁶, Lenka Szczuková⁷, Prodromos Sidiropoulos⁸, Irini Flouri⁸, Alexandros Drosos⁹, Burkhard Möller¹⁰, Michael J. Nissen¹¹, Rüdiger B. Müller¹², Almut Scherer¹³, Neil McHugh³ , and Alison Nightingale³

ABSTRACT. Objective. To investigate whether tumor necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy.

Methods. Five PsA biologics cohorts were investigated between 2000 and 2015: the ATTRA registry (Czech Republic); the Swiss Clinical Quality Management PsA registry; the Hellenic Registry of Biologics Therapies (Greece); the University of Bari PsA biologics database (Italy); and the Bath PsA cohort (UK). Drug persistence was analyzed using Kaplan-Meier and equality of survival using log-rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on (1) the combined Italian/Swiss cohorts for change in rate of Disease Activity Score in 28 joints (DAS28); and (2) the combined Italian, Swiss, and Bath cohorts for change in rate of Health Assessment Questionnaire (HAQ).

Results. In total, 2294 patients were eligible for the drug survival analysis. In the Swiss ($P = 0.002$), Greek ($P = 0.021$), and Bath ($P = 0.014$) databases, patients starting TNFi in combination with methotrexate had longer drug survival compared to monotherapy, while in Italy the monotherapy group persisted longer ($P = 0.030$). In eligible patients from the combined Italian/Swiss dataset ($n = 1056$), there was no significant difference between treatment arms in rate of change of DAS28. Similarly, when also including the Bath cohort ($n = 1205$), there was no significant difference in rate of change of HAQ.

Conclusion. Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.

Key Indexing Terms: comparative effectiveness, drug survival, methotrexate, psoriatic arthritis, TNF inhibitor

The study was funded by a nonrestricted investigator-initiated award from Pfizer.

¹M.L. Thomas, PhD, Department of Mathematical Science, University of Bath, Bath, UK; ²G. Shaddick, PhD, Department of Mathematics, University of Exeter, Exeter, UK; ³R. Charlton, PhD, N. McHugh, MBChB, MD, FRCP, FRCPath, A. Nightingale, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; ⁴C. Cavill, BSc, R. Holland, MD, Royal National Hospital for Rheumatic Diseases, Bath, UK;

⁵F. Iannone, MD, PhD, G. Lapadula, MD, S. Lopriore, MD, Rheumatology Unit—DETO, University of Bari, Bari, Italy; ⁶J. Závada, MD, PhD, K. Pavelka, MD, PhD, Institute of Rheumatology, Prague, Czech Republic; ⁷M. Uher, MSc, L. Szczuková, MD, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic;

⁸P. Sidiropoulos, MD, PhD, I. Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece; ⁹A. Drosos, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; ¹⁰B. Möller, Professor, Department of Rheumatology, Immunology & Allergy, Inselspital, University Hospital Bern, Bern, Switzerland;

¹¹M.J. Nissen, MBBS, FRACP, Department of Rheumatology, University Hospital Geneva, Geneva, Switzerland; ¹²R.B. Müller, MD, Cantonal Hospital, Lucerne, Switzerland; ¹³A. Scherer, PhD, SCQM Foundation, Zürich, Switzerland.

N. McHugh and A. Nightingale are joint senior authors.

NM, AN, RC, MT and CC report grants from Pfizer during the conduct of the study. NM reports personal fees from AbbVie and Lilly and grants from Lilly outside the submitted work. CC reports grants from Celgene, Lilly and Novartis and personal fees from Novartis outside of the submitted work. FI reports personal fees from AbbVie, BMS, Novartis, Pfizer, Lilly, UCB and MSD outside the submitted work. GL reports personal fees from AbbVie, BMS, Novartis, Pfizer, and MSD outside the submitted work. KP reports honoraria for consultations and speaker fees from AbbVie, Pfizer, UCB, Lilly, Novartis, and Roche outside the submitted work. PS reports that the Hellenic Registry for Biologic Therapies was supported in part by the Hellenic Rheumatology Society through unrestricted grants from Schering-Plough, AbbVie, Pfizer, Bristol Myers Squibb, and Roche during the conduct of the study. These companies had no role in study design, collection, analysis, and interpretation of the data and in the writing of the manuscript. PS also reports grants and personal fees from the pharma industry through the University of Crete Special Account for Research, outside the submitted work.

Address correspondence to Prof. N. McHugh, Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK. Email: n.j.mchugh@bath.ac.uk.

Accepted for publication March 18, 2020.

Tumor necrosis factor inhibitors (TNFi) are an effective treatment for psoriatic arthritis (PsA)¹ and are generally prescribed following the failure of initial treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARD), of which methotrexate (MTX) is the most widely used. TNFi may be prescribed as monotherapy or in combination with csDMARD with 51% to 79% of patients using TNFi in combination with MTX². A systematic review of randomized controlled trials (RCT) and observational studies of TNFi monotherapy versus TNFi combination therapy with MTX did not find any difference in efficacy for peripheral disease, but there was some evidence of benefit of combination therapy on TNFi drug survival². While there is clear evidence for the benefit of combination TNFi plus csDMARD in rheumatoid arthritis (RA)³, the value of combination therapy in PsA remains unresolved⁴, and this may explain the variability observed in clinical practice and the lack of clarity in current treatment guidelines^{5,6}.

Biologics registries have been set up globally to investigate the long-term efficacy and safety of TNFi. The aim of this study was to combine data from multiple European TNFi databases to describe the utilization patterns of TNFi monotherapy and combination therapy in PsA and to investigate the comparative effectiveness of TNFi monotherapy versus combination therapy in terms of drug survival and patient outcomes.

MATERIALS AND METHODS

Participating databases. An invitation to participate in the study was sent to all European biologics registries known to collect data on patients with PsA. Three biologics registries and 2 hospital-based PsA biologics cohorts agreed to participate and were included in the study: the ATTRA registry, Czech Republic (the “Czech database”); the Swiss Clinical Quality Management (SCQM) in Rheumatic Diseases PsA registry, Switzerland (the “Swiss Database”); the Hellenic Registry of Biologic Therapies (HeRBT), Greece (the “Greek Database”); the University of Bari School of Medicine PsA biologics database, Italy (the “Italian Database”); and the Royal National Hospital for Rheumatic Diseases, Bath, UK PsA cohort (the “Bath Database”). The hospital-based Italian and Bath databases are both prospective cohort studies that have submitted data to the biologics registry that was established by the Italian Group for the Study of Early Arthritis (GISEA) and the British Society for Rheumatology Rheumatoid Arthritis Biologics Registry (BSRBR-RA), respectively, and were therefore deemed of sufficiently high quality in terms of data collection to be included in the study. Ethics approval was granted for each of the 5 cohorts (for the lead center, this was by the South West-Central Bristol National Research Ethics Service Committee, approval number BA74/00-01; all other approvals can be found in Supplementary Table 1 (available with the online version of this article). A summary of data collection for each database is shown in Supplementary Table 2.

Study population. The study period ran from January 1, 2000 to December 31, 2015. We included all adults (≥ 18 yrs) with a clinical diagnosis of PsA who were new (first-line) users of TNFi during the study period and who were registered in their respective biologics database from the time of first TNFi prescription. Patients who had been prescribed any other type of biologic DMARD before their first TNFi prescription were excluded. Patient and disease characteristics at baseline were extracted from the databases.

Drug exposure and patient follow-up. Recorded prescription data was used to determine exposure status during the follow-up period. Exposure to treatment groups was classified at baseline into: (1) TNFi monotherapy; and (2) TNFi combination therapy with MTX (this group was also included in a category of TNFi combination therapy with any csDMARD, including MTX).

Patient follow-up and outcome measures. Patients were followed until their censoring date, which was the earliest of (1) the time of discontinuation of their first TNFi agent, defined as discontinuation of therapy for at least 3 months; or (2) the date that they were lost to follow-up; or (3) the date of their last follow-up on the biologics database, whichever was the earliest. Drug persistence was defined as the time from TNFi to censoring date.

The primary outcome measure for the comparative effectiveness analyses was rate of change of disease activity, measured using the Disease Activity Score in 28 joints (DAS28)⁷, during the follow-up period. The secondary outcome measure was rate of change in physical function, measured using the Health Assessment Questionnaire (HAQ)⁸, during the follow-up period.

Statistical analyses. Statistical analyses were undertaken using R statistical software⁹. Individual patient data from the Bath, Italian, and Swiss databases were analyzed at the University of Bath; the Czech and Greek data were analyzed locally. A full description of the statistical methods can be found in the Supplementary Data 1 (available with the online version of this article).

Drug survival. Drug survival was analyzed using Kaplan-Meier survival estimates and defined as time from TNFi initiation to censoring date, stratified by treatment group, age at TNFi initiation, and sex. The median time from baseline to discontinuation of first TNFi, with 95% CI, was calculated from the survival function. The equality of the survival functions was compared using log-rank tests.

Comparative effectiveness. Due to the complexity of the comparative effectiveness analyses modeling, we only included data for which we had individual patient data at the University of Bath (Bath, Italian, and Swiss databases). Initial data analysis included examining changes in DAS28 and HAQ over time, without adjustment for covariates.

Comparative effectiveness analyses were based on an intention-to-treat analysis approach using negative binomial regression. Comparisons were made between TNFi monotherapy and (1) any TNFi + csDMARD and, as a subgroup analysis, we also compared to (2) TNFi + MTX. For HAQ, in order to allow for the observed excess of zeros, a zero-inflated negative binomial model was used, with a consistent set of covariates used for both components of the model. Statistical comparisons were based on the relative difference in rates of change in disease score between treatments.

While each registry had planned follow-up periods (for example 3, 6, 12 months), the actual dates of follow-up varied substantially around these, with additional follow-up appointments also being recorded. Attempting to classify these variable follow-up appointments into specific follow-up periods (e.g., change at 3 months and 6 months) resulted in significant loss of data. Therefore, we included all follow-up data in the analysis rather than planned timepoints.

The regression models were adjusted for age at TNFi initiation and sex. Differences between rates of improvement in the 2 treatment groups were obtained by including an interaction term between time and treatment group in the regression models. To account for any confounding by indication, we developed database-specific propensity score (PS) models, using all available baseline data, to calculate the individual PS for treatment to monotherapy or combination therapy. All covariates that were not explicitly included in the model were included in the PS models, including clinical characteristics such as disease duration.

Missing values in any explanatory variable (where $< 70\%$ were missing) were estimated using multiple imputation using the Amelia II package in R¹⁰. In order to test for a significant difference in the rate of change for each treatment group, estimates of the log relative risk (RR) with standard error associated with the interaction between treatment group and time were extracted and then combined to give an overall estimate of RR, together with a combined standard error using Rubin's rule.

RESULTS

There were 2294 eligible patients identified from the contributing databases, of which 34% started treatment as monotherapy

and 66% as combination therapy. Table 1 summarizes requirements for access to TNFi and baseline patient characteristics. Clinical guidelines for access to TNFi differed across countries. The effect of the guidelines on measures of disease severity and activity at TNFi initiation was reflected in the relatively lower HAQ and DAS28 scores in the Swiss database and higher baseline scores in the Bath database. Comorbidity data were not consistently recorded across all of the databases; however, in general, the proportion of patients with significant comorbidities was < 5% of each study population, with the exception of a prevalence of latent tuberculosis (TB) of 13% in the Italian database due to screening for latent TB.

Drug utilization. In all centers, TNFi were more commonly prescribed in combination with a csDMARD than as monotherapy and MTX was the csDMARD most frequently prescribed (Table 1). Changes in baseline prescribing during the study period are shown in Supplementary Figure 1 (available with the online version of this article). Patient characteristics and baseline disease activity and severity were generally similar across treatment groups within the databases (Table 1). Adalimumab (ADA) and etanercept (ETN) were the most frequently prescribed TNFi in all databases other than the Greek database, where 47.7% of patients were treated with infliximab (IFX). Supplementary Table 3 shows the TNFi products prescribed at baseline. The majority of patients (81.7% monotherapy and 66.0% combination therapy) did not have changes to their baseline treatment regimen before discontinuing their first TNFi, and > 85% of these changes were made > 12 months after TNFi initiation.

Drug survival. The Kaplan-Meier survival curves for drug survival on first TNFi, stratified by database and baseline treatment regimen, are shown for monotherapy versus any csDMARD combination therapy in Figure 1 and monotherapy versus combination therapy with MTX in Supplementary Figure 2 (available with the online version of this article). Figure 2 shows the Kaplan-Meier survival curves for drug survival stratified by sex and Supplementary Figure 3 shows them stratified by age. Median survival times are shown in Table 2. Discontinuation of first TNFi was earliest in patients in the Swiss database (median 2.8 yrs, 95% CI 1.5–3.7); patients in the Greek database had the longest median survival time (6.9 yrs, 95% CI 4.9–not available, defined as < 50% dropout).

In all but the Italian database, patients on combination therapy had longer survival on their first TNFi than those on monotherapy. This ranged from 0.5 to 2.9 years and the difference was statistically significant in the Bath and Swiss databases for any combination and in the Bath, Greek, and Swiss databases for combination with MTX (Figure 1, Table 2). In the Italian database, patients on monotherapy persisted significantly longer on their first TNFi than those on combination therapy, but this difference did not remain significant when the analyses were limited to combination therapy with MTX. In all but the Czech database, where we observed no difference, men persisted significantly longer on their first TNFi than women (Figure 2 and Table 2).

Comparative effectiveness. The analysis of rate of change in DAS28 included 1056 patients from the Swiss and Italian databases with a DAS28 score recorded; 441 were prescribed TNFi monotherapy at baseline and 615 were prescribed combination therapy with any csDMARD, of whom 442 were prescribed TNFi + MTX. Sixty-eight patients from the Swiss database were excluded because they did not have a DAS28 score recorded. The analysis of rate of change in HAQ included 1205 patients from the Bath, Swiss, and Italian databases (504 monotherapy and 701 combination therapy with any csDMARD of whom 505 were exposed to TNFi + MTX). We excluded 107 Swiss patients and 11 Bath patients who had no HAQ scores recorded before their censoring dates.

Within the database-specific PS models for both the DAS28 and HAQ analyses, patients who had previously used csDMARD had a higher baseline HAQ and those who had a history of dactylitis were significantly more likely to be prescribed combination therapy. None of the recorded comorbidities were significant in the models and there was no difference in the PS for TNFi + any csDMARD, and TNFi + MTX groups. None of the variables included in the Bath PS model were significantly associated with treatment allocation.

Figure 3 and Figure 4 show the change in DAS28 and HAQ over time, respectively, unadjusted for any covariates. In both the DAS28 and HAQ analyses, patients on combination therapy had higher baseline scores than patients on monotherapy. The pattern of rate of change was similar in both analyses, with scores dropping sharply in the first year after treatment initiation, increasing slightly then stabilizing from 12 months onwards.

There was no statistically significant difference in rate of change of DAS28 between patients on TNFi monotherapy with those on combination therapy with any csDMARD [combined adjusted RR (RRadj) 0.98, 95% CI 0.95–1.03] or on monotherapy compared with TNFi + MTX (combined RRadj 0.98, 95% CI 0.95–1.02). There was no statistically significant difference in rate of change of HAQ in patients on monotherapy compared to those on combination therapy with any csDMARD (combined RRadj 1.02, 95% CI 0.98–1.06) or when compared to those on TNFi + MTX (combined RRadj 1.02, 95% CI 0.99–1.07). Inclusion of the PS in the models did not significantly change the combined RR.

There were no notable differences in reasons for stopping the first TNFi between the databases. Supplementary Table 4 (available with the online version of this article) summarizes the reasons for treatment discontinuation stratified by database and baseline treatment regimen. Overall 23.5% of the 1323 patients from the Bath, Italian, and Swiss databases discontinued treatment in the first year after TNFi initiation and the proportion was lower in patients exposed to TNFi + MTX (21.8%) than those on monotherapy (25.9%) or TNFi + non-MTX csDMARD (26.5%). Lack of treatment efficacy was the most frequently recorded reason for discontinuation (9.8% overall; 11.3% monotherapy, 7.9% TNFi + MTX, and 10.8% TNFi + non-MTX csDMARD) followed by adverse drug reactions (7.6% overall; 7.0% monotherapy, 6.5% TNFi + MTX, and

Table 1. Patient characteristics stratified by biologics database and baseline treatment regimen.

Baseline Characteristic	ATTRA, Czech Republic			Bari, Italy			Bath, UK			HeRBT, Greece			SCQM, Switzerland		
No. patients Criteria for PsA	658 (358 males, 300 females) Moll & Wright to 2012; Moll & Wright or CASPAR from 2012			300 (140 males, 160 females) CASPAR			199 (100 males, 99 females) CASPAR			314 (142 males, 172 females) Clinical diagnosis by a rheumatologist (usually using CASPAR)			824 (407 males, 417 females) Clinical diagnosis by a rheumatologist		
Requirements for starting TNFi	PsA not adequately controlled using csDMARD			EULAR guidelines: Inadequate response to ≥ 1 csDMARD			EULAR/BSR guidelines: peripheral arthritis with ≥ 3 SJC and ≥ 3 TJC and inadequate response to ≥ 2 csDMARD			HSR guidelines: peripheral arthritis with ≥ 3 SJC and ≥ 3 TJC and inadequate response to ≥ 2 csDMARD or BASDAI > 4 and inadequate response ≥ 2 NSAID			No rigid guidelines but generally active disease with inadequate response to ≥ 1 csDMARD		
Baseline Treatment Regimen	Mono	Combo Any csDMARD	Combo MTX	Mono	Combo Any csDMARD	Combo MTX	Mono	Combo Any csDMARD	Combo MTX	Mono	Combo Any csDMARD	Combo MTX	Mono	Combo Any csDMARD	
No. patients, n (%)	141 (21.4)	517 (78.6)	363 (55.2)	110 (36.7)	190 (63.3)	146 (48.7)	86 (43.2)	113 (56.8)	75 (37.7)	77 (24.5)	237 (75.4)	204 (65.0)	363 (44.1)	461 (55.9)	
Males, %	48.2	52.2	50.1	51.8	43.8	43.2	46.5	53.1	49.3	61	52.7	53.4	52.3	47.1	
Age at TNFi initiation, yrs, median (IQR)	45.0 (37.0–54.0)	48.0 (39.0–55.0)	48.0 (38.0–54.0)	49.5 (38.0–59.0)	48.0 (39.0–56.0)	48.0 (39.0–55.8)	48.0 (40.0–56.0)	51.0 (43.0–61.0)	51.0 (43.5–62.0)	48.0 (37.0–57.5)	51.0 (39.2–59.0)	51.4 (39.0–59.1)	47.0 (38.0–56.5)	48.0 (40.0–56.0)	
Duration of PsA, yrs, median (IQR)	6.0 (2.3–11.3)	6.9 (2.9–11.8)	6.7 (2.6–11.9)	3.0 (1.0–7.0)	3.0 (1.0–6.0)	3.0 (1.0–5.3)	9.0 (4.0–22.0)	12.0 (6.0–19.5)	11.0 (6.0–17.0)	5.5 (1.1–14.4)	5.5 (1.9–11.4)	5.0 (1.5–11.0)	2.0 (0.0–7.0)	3.0 (0.0–7.0)	
Mean (SD) duration of follow-up, yrs	4.0 (3.4)	3.6 (2.8)	3.7 (2.8)	6.4 (3.3)	5.6 (3.4)	5.7 (3.5)	4.6 (3.1)	4.9 (2.6)	4.7 (2.4)	2.6 (2.5)	3.0 (2.0)	3.02 (2.8)	3.8 (3.3)	4.4 (3.3)	
Current smoker, %	4.3	6.0	5.8	20.0	24.7	21.2	14.0	13.3	14.7	16.9	7.2	7.8	10.2	10.4	
Current nonsmoker, %	22.0	29.4	30.0	80.0	75.3	78.8	72.1	82.3	80.0	9.1	10.1	10.8	28.7	29.1	
Smoking unknown, %	73.8	64.6	64.2	0.0	0.0	0.0	13.9	4.4	5.3	74.0	82.7	81.4	61.2	60.5	
BMI < 25, %	19.1	22.4	20.7	29.1	32.1	32.1	9.3	19.5	14.6	24.7	14.3	14.2	33.3	29.5	
BMI 25–29, %	19.9	29.0	28.1	38.2	41.6	41.8	37.2	37.2	42.7	6.5	11.4	13.2	28.7	30.2	
BMI ≥ 30, %	14.2	20.5	20.9	30.9	24.7	24.6	40.7	39.8	38.6	6.5	11.4	13.2	18.2	19.1	
BMI unknown, %	46.8	28.0	30.3	1.8	1.6	1.5	12.8	22.2	4.1	68.8	74.3	72.5	19.8	21.2	
DAS28, median (IQR)	5.1 (4.2–5.7)	5.3 (4.7–6.0)	5.4 (4.7–6.0)	4.0 (3.2–4.7)	4.1 (3.3–5.0)	4.1 (3.3–5.0)	–	–	–	4.1 (2.9–5.2)	5.0 (4.0–6.0)	5.0 (3.9–5.9)	3.2 (2.3–4.3)	3.5 (2.7–4.3)	
HAQ (mHAQ for Greece), median (IQR)*	1.3 (0.9–1.8)	1.3 (0.9–1.6)	1.3 (0.9–1.6)	0.8 (0.1–1.4)	0.8 (0.3–1.5)	0.9 (0.3–1.5)	1.3 (0.5–1.9)	1.1 (0.6–1.9)	1.1 (0.5–1.9)	0.8 (0.4–1.1)	0.8 (0.3–1.1)	0.8 (0.3–1.1)	0.8 (0.3–1.3)	0.8 (0.3–1.3)	

*Rounded to 1 decimal place. Data in italics indicate that > 50% of the data values were missing. BASDAI: Bath Ankylosing Spondylitis Activity Index; BSR: British Society for Rheumatology TNFi guidelines; CASPAR: Classification Criteria for Psoriatic Arthritis; csDMARD: conventional synthetic disease-modifying antirheumatic drug (note that the category “any csDMARD” includes patient-prescribed combination therapy with MTX); DAS28: Disease Activity Score in 28 joints; EULAR: European League Against Rheumatism TNFi guidelines; HAQ: Health Assessment Questionnaire; HeRBT: Hellenic Registry of Biologics Therapies; HSR: Hellenic Society for Rheumatology; mHAQ: modified HAQ; Mono: monotherapy; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug; PsA: psoriatic arthritis; SCQM: Swiss Clinical Quality Management; SJC: swollen joint count; TJC: tender joint count; TNFi: tumor necrosis factor inhibitor.




Figure 1. Kaplan-Meier survival estimates from TNFi initiation to discontinuation of first TNFi or data censoring stratified by baseline treatment regimen, monotherapy compared with TNFi + csDMARD combination therapy. csDMARD: conventional synthetic disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitor.




Figure 2. Kaplan-Meier survival estimates from TNFi initiation to discontinuation of first TNFi or data censoring stratified by sex. TNFi: tumor necrosis factor inhibitor.

9.4% TNFi + non-MTX csDMARD). Lack of treatment efficacy remained the most frequently recorded reason for treatment discontinuation at any time after TNFi initiation, followed by adverse drug reactions.

DISCUSSION

The results of this multiregistry study are consistent with previous

studies of TNFi monotherapy versus combination therapy treatment in patients with PsA. We found no significant difference in clinical outcome between the treatment groups, which is in line with observational studies in Sweden¹¹, Norway^{12,13}, the UK¹⁴, Denmark¹⁵, and Finland¹⁶. A recent RCT found that combination therapy of ETN and MTX may not improve radiographic progression compared with ETN monotherapy,

Table 2. Median survival times from TNFi initiation to discontinuation of first TNFi stratified by baseline treatment regimen and database.

	ATTRA, Czech Republic		Bari, Italy		Bath, UK		HeBRT, Greece		SCQM, Switzerland	
	n	Median Survival Time, Years (95% CI)	n	Median Survival Time, Years (95% CI)	n	Median Survival Time, Years (95% CI)	n	Median Survival Time, Years (95% CI)	n	Median Survival Time, Years (95% CI)
All	658	5.9 (4.7–7.6)	300	4.9 (4.1–6.6)	199	4.8 (3.6–6.6)	314	6.9 (4.9–NA)	824	2.8 (2.5–3.7)
Treatment regimen at baseline (combination therapy with any csDMARD including MTX)										
Monotherapy	141	4.8 (3.8–NA)	110	6.9 (4.7–NA)	86	3.2 (1.3–6.5)	77	4.3 (2.9–8.3)	363	2.6 (1.7–3.3)
Combination therapy	517	5.9 (4.7–7.3)	190	4.3 (3.2–6.2)	113	6.1 (4.5–NA)	237	7.2 (5.3–NA)	461	3.1 (2.6–4.7)
<i>P</i> *		0.6054		0.0303		0.0105		0.0609		0.0288
Treatment regimen at baseline (combination therapy with MTX)										
Monotherapy	141	4.8 (3.5–NA)	110	6.9 (4.7–NA)	86	3.2 (1.3–6.5)	77	4.3 (2.9–8.3)	363	2.6 (1.7–3.3)
Combination therapy	363	6.3 (4.5–8.0)	146	4.9 (3.9–6.6)	75	6.1 (4.5–NA)	204	NA (5.4–NA)	320	4.3 (3.0–6.3)
<i>P</i> *		0.5550		0.0737		0.0135		0.0208		0.0020
Age, yrs										
18–49	370	6.6 (4.3–8.9)	157	6.0 (4.1–8.2)	99	5.1 (3.6–NA)	157	7.2 (4.9–NA)	447	3.8 (2.8–4.6)
50+	288	5.4 (4.4–7.6)	143	4.5 (3.4–6.2)	100	4.8 (3.2–NA)	157	6.9 (4.3–NA)	377	2.2 (1.6–2.9)
<i>P</i> *		0.9958		0.3319		0.7923		0.9289		0.0089
Sex										
Female	320	5.7 (4.2–8.2)	160	3.8 (2.7–4.9)	99	2.4 (1.6–6.1)	142	4.3 (2.8–7.8)	417	2.0 (1.5–2.7)
Male	338	5.9 (4.6–8.9)	140	7.0 (5.5–10.7)	100	6.6 (4.8–NA)	172	NA (5.9–NA)	407	4.2 (3.2–5.6)
<i>P</i> *		0.6075		0.0036		0.0100		0.0035		< 0.0001

**P* value from log-rank test to compare the equality of the survival. csDMARD: conventional synthetic disease-modifying antirheumatic drug (note that the category “any csDMARD” includes patient-prescribed combination therapy with MTX); HeBRT: Hellenic Registry of Biologics Therapies; MTX: methotrexate; NA: not available (did not reach 50% dropout); SCQM: Swiss Clinical Quality Management; TNFi: tumor necrosis factor inhibitor.

although combination therapy had slightly greater efficacy for dermatologic endpoints¹⁷. In the Bath, Greek, and Swiss databases, patients were found to persist significantly longer on their first TNFi when prescribed in combination with MTX than patients on TNFi monotherapy. This has also been observed in studies in Denmark^{15,18}, Norway¹³, Sweden¹¹, and Italy^{19,20}; in Denmark, however, this was only found when adjustments were made for other baseline variables¹⁵. Although some studies have not reported significantly longer persistence with MTX^{16,21,22}, no study has reported longer persistence for patients on monotherapy as was observed in the Italian database. One study in the US, however, did report different findings for the individual TNFi, with significantly longer persistence for ETN as monotherapy although the opposite was observed for IFX and there was no difference between treatment groups for ADA²². Our study, however, did not look at individual TNFi and so could not determine whether the benefit of combination therapy varied by TNFi. Our study did find some evidence that a lower proportion of patients on TNFi + MTX stop in the first year of treatment due to a lack of treatment efficacy or adverse drug reactions. The reason for this finding is not clear and whether there is an explanatory biological mechanism such as the inhibition of the development of antidrug antibodies needs further investigation.

A study in Sweden had found patients without MTX showed significantly lower drug survival due to adverse events but did not find a difference for treatment failure¹¹. Our study found that in all but the Czech database, males persist significantly longer

on their first TNFi than females, and this has been observed in some studies looking at PsA^{15,19,20,21,23,24,25,26} but not others^{11,13}. This finding has also been reported for RA and ankylosing spondylitis^{27,28,29}. Other predictors that have been found to be associated with drug survival include having a higher baseline C-reactive protein^{11,15}, a low baseline visual analog scale score for global health¹⁵, being a nonsmoker¹³, and absence of baseline comorbidity^{21,26,30}, including a metabolic syndrome-related comorbidity³¹ and obesity³². Predictors have also been reported to vary depending on the reason for discontinuation, with some being associated with discontinuation for adverse events and others for a lack of efficacy^{11,15}.

This study aimed to combine European biologics registry data to investigate treatment utilization patterns and outcomes in PsA. The prescribing criteria and disease activity scores, however, were not standardized across databases and as such the drug utilization analyses were carried out separately. For the comparative effectiveness analyses, limitations included the fact that individual patient-level data were not available for all databases and also that HAQ was the only outcome measure commonly recorded. For the databases where individual-level data was available and outcome measures were common, we have, however, demonstrated that statistical models using individual patient data can be developed to combine data that have been collected in different healthcare contexts but using similar study designs. Although patients from the different databases had differing baseline disease activity and severity scores due to differences in access requirements to TNFi across Europe,




Figure 3. DAS28 over time, unadjusted for any covariates, among patients from the Italian and Swiss databases from TNFi initiation to the earliest of: (1) discontinuation of first TNFi; or (2) date of data censoring; or (3) 60 months follow-up for (3a) monotherapy versus combination TNFi + any csDMARD and (3b) monotherapy versus combination TNFi + MTX. csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28: Disease Activity Score in 28 joints; MTX: methotrexate; TNFi: tumor necrosis factor inhibitor.

we have demonstrated that clinical outcome measures can be combined by analyzing rate of change rather than absolute change in DAS28 or HAQ from baseline, which is a methodological strength of the study.

Another limitation of the data was that the actual dates of follow-up varied considerably. It was therefore necessary, when performing the modeling for the comparative effectiveness, to include all follow-up data and model time as a continuous

covariate, as restricting to specific time periods would have resulted in a significant loss of data and the potential for bias.

We designed the study to use DAS28 as the primary outcome measure and HAQ as the secondary outcome measure because the majority of biologics databases have been set up to primarily collect treatment effectiveness and safety data in patients with RA and we therefore expected that DAS28 would be the outcome measure more readily available. While DAS28 has been




Figure 4. HAQ over time, unadjusted for any covariates, among patients from the Bath, Italian, and Swiss databases from TNFi initiation to the earliest of: (1) discontinuation of first TNFi; or (2) date of data censoring; or (3) 60 months follow-up for (4a) monotherapy versus combination TNFi + any csDMARD and (4b) monotherapy versus combination TNFi + MTX. csDMARD: conventional synthetic disease-modifying antirheumatic drug; HAQ: Health Assessment Questionnaire; MTX: methotrexate; TNFi: tumor necrosis factor inhibitor.

validated for use in PsA, its usefulness is limited by the exclusion of the ankle joints and feet, which are frequently affected in PsA. We did, however, find that all databases collected data on HAQ, which is arguably a more relevant outcome measure for studies of PsA. However, none of the databases collected data on all of the outcome measures in the more disease-specific Outcome Measures for Rheumatology (OMERACT) core set of outcomes for PsA³³. As a result, our analysis of the effectiveness of TNFi treatment is limited to physical function and cannot take into

account other domains such as pain, fatigue, work productivity, enthesitis, or skin disease activity and health-related quality of life, which are important to people with PsA; these other domains are also important when carrying out cost-effectiveness analyses of treatment.

We used PS modeling to attempt to minimize the effect of confounding by indication and channeling bias; however, the effectiveness of PS adjustment for treatment allocation is limited by the variables collected in the databases and whether they are

the variables that might be associated with treatment allocation. We used all available data within the PS models, and both a history of dactylitis and higher baseline HAQ scores predicted the use of combination treatment. However, there were issues with large amounts of missing data for some variables and we had no measures of previous treatment compliance, tolerance, or success. Therefore, we cannot rule out the potential for uncontrolled confounding by indication and it is not possible to predict the effect that this might have on the findings of the study.

In conclusion, we have demonstrated the feasibility of combining biologics registry and database data to investigate the comparative effectiveness of TNFi treatment for PsA, but as with all observational studies, the results need to be interpreted with caution. We have found that while there is no significant difference in treatment outcome, as measured using DAS28 and HAQ, patients on combination therapy persist longer on their first TNFi than those on monotherapy. Sex appears to be a major risk factor in determining TNFi survival, with males persisting for longer.

ACKNOWLEDGMENT

We would like to thank all patients and rheumatologists for contributing data to the respective registries. For the SCQM, a list of rheumatology offices and hospitals that contribute data can be found on www.scqm.ch/institutions. The SCQM is financially supported by pharmaceutical companies (www.scqm.ch/sponsors).

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES

1. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2012;71:319-26.
2. Behrens F, Cañete JD, Olivier I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. *Rheumatology* 2015;54:915-26.
3. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2010;69:964-75.
4. Elmamoun M, Chandran V. Role of Methotrexate in the Management of Psoriatic Arthritis. *Drugs* 2018;78:611-19.
5. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer LM, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. *Arthritis Rheumatol* 2016;68:1060-71.
6. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Care Res* 2019;71:2-29.
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
8. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
9. R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from www.R-project.org
10. Honaker J, King G, Blackwell M. Amelia II: a program for missing data. *J Stat Softw* 2011;45:1-47.
11. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis* 2008;67:364-69.
12. Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. *Ann Rheum Dis* 2007;66:1038-42.
13. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg ÅS, Rødevand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis* 2014;73:132-37.
14. Saad AA, Ashcroft DM, Watson KD, Symmons DPM, Noyce PR, Hyrich KL, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. *Rheumatology* 2010; 49:697-705.
15. Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2011;63:382-90.
16. Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. *Semin Arthritis Rheum* 2017;46:732-39.
17. Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. *Arthritis Rheumatol* 2019;71:1112-24.
18. Glintborg B, Gudbjornsson B, Steen Krogh N, Omerovic E, Manilo N, Holland-Fischer M, et al. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. *Rheumatology* 2014;53:2100-9.
19. Favalli EG, Selmi C, Becciolini A, Biggoggero M, Ariani A, Santilli D, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. *Arthritis Care Res* 2017;69:867-74.
20. Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, et al. Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence. *J Rheumatol* 2018;45:785-94.
21. Fagerli KM, Kearsley-Fleet L, Watson KD, Packham J, BSRBR-RA Contributors Group, Symmons DPM, et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. *RMD Open* 2018;4:e000596.
22. Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corona registry. *RMD Open* 2015;1:e000181.
23. Højgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Glintborg B, et al. Gender differences in biologic treatment outcomes—a study of 1750 patients with psoriatic arthritis using

- Danish Health Care Registers. *Rheumatology* 2018;57:1651-60.
24. Generali E, Sciré CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. *Isr Med Assoc J* 2016;18:203-8.
 25. Ribeiro da Silva MR, Ribeiro Dos Santos JB, Maciel Almeida A, Itria A, Maria Kakehasi A, Alvares Teodoro J, et al. Medication persistence for psoriatic arthritis in a Brazilian real-world setting. *Future Sci OA* 2019;5:FSO369.
 26. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. *Arthritis Res Ther* 2009;11:R52.
 27. Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. *RMD Open* 2015;1:e000017.
 28. Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, et al. The sex influence on response to tumor necrosis factor- α inhibitors and remission in axial spondyloarthritis. *J Rheumatol* 2018;45:195-201.
 29. Hyrich KL, Watson KD, Silman AJ, Symmons DPM, BSRBR. Predictors of response to anti-TNF- α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology* 2006;45:1558-65.
 30. Ballegaard C, Højgaard P, Dreyer L, Cordtz R, Jørgensen TS, Skougaard M, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. *Arthritis Care Res* 2018;70:592-99.
 31. Stober C, Weiyu Y, Guruparan T, Htut E, Clunie G, Jadon D. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. *Rheumatology* 2018;57:158-63.
 32. Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor- α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. *Rheumatology* 2016;55:2191-99.
 33. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Ann Rheum Dis* 2017;76:673-80.